Amandeep Godara
( out of 57 reviews )

Amandeep Godara, MBBS

Languages spoken: English, Hindi

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

801-587-4687

  • Dr. Amandeep Godara completed his Hematology-Oncology fellowship at Tufts Medical Center with a clinical and research interest in plasma cell disorders. His research focuses on developing new therapeutic targets and tools for assessment of treatment response in Multiple Myeloma, Amyloidosis and other monoclonal gammopathies. His work has been presented at national and international scientific meetings. He was the recipient of Amyloidosis Foundation David Seldin, MD, PhD Memorial Research Grant in 2019. He also received training in blood and marrow transplantation at Stanford University. He completed his medical school at Government Medical College, Aurangabad, India and his internal medicine residency at Wayne State University. Dr. Godara treats patients with Multiple Myeloma, Amyloidosis, Waldenstrom’s Macroglobulinemia, and other plasma cell disorders.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    4.8 /5
    ( out of 57 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    September 25, 2023
    HUNTSMAN CANCER CENTER

    After my appointment with Dr Godara I understand my cancer better as well as the stem cell transplant procedure.

    September 20, 2023
    HUNTSMAN CANCER CENTER

    He is the first doctor that gave me hope that my symptoms could be explained, diagnosed, and treated.

    September 19, 2023
    HUNTSMAN CANCER CENTER

    I felt he truly cared for getting me the best care possible. He delivered info to me in a way that was not way over my head and he took time to reassure me and listen to questions and concerns. He also has done a follow call or two after release from hospital there which I appreciated just to go over things again.

    September 14, 2023
    HUNTSMAN CANCER CENTER

    Like the doctor very much!

    September 14, 2023
    HUNTSMAN CANCER CENTER

    He is the best! He always, without fail, really listens to me and my concerns. He takes time to address my concerns and answer any and all of my questions. Like I said, he's great! Professional, knowledgeable, sincere, kind. Thanks Dr. Godara!

    September 05, 2023
    HUNTSMAN CANCER CENTER

    Dr. Godara was awesome. He discussed test results and treatment plans with us and we were relieved. He explained some test results and things we need to watch for. He was very personable and we liked him much better than previous Dr. K.

    September 02, 2023
    HUNTSMAN CANCER CENTER

    Dr. Godara is kind, knowledgeable and thorough. Can't ask for anyone better!

    August 31, 2023
    HUNTSMAN CANCER CENTER

    Dr. Godara continues to show empathy and remembers details about my case and is diligent in followup and care.

    August 30, 2023
    HUNTSMAN CANCER CENTER

    I'm most interested in curing the cause versus treating the symptoms.

    See More Patient Comments

  • Dr. Amandeep Godara completed his Hematology-Oncology fellowship at Tufts Medical Center with a clinical and research interest in plasma cell disorders. His research focuses on developing new therapeutic targets and tools for assessment of treatment response in Multiple Myeloma, Amyloidosis and other monoclonal gammopathies. His work has been presented at national and international scientific meetings. He was the recipient of Amyloidosis Foundation David Seldin, MD, PhD Memorial Research Grant in 2019. He also received training in blood and marrow transplantation at Stanford University. He completed his medical school at Government Medical College, Aurangabad, India and his internal medicine residency at Wayne State University. Dr. Godara treats patients with Multiple Myeloma, Amyloidosis, Waldenstrom’s Macroglobulinemia, and other plasma cell disorders.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Fellowship Hematology-Oncology - Tufts Medical Center Fellow
    Bone Marrow Transplantation and Immunotherapy - Stanford University School of Medicine Fellow
    Residency Internal Medicine - Wayne State University School of Medicine Resident
    Internal Medicine - Wayne State University School of Medicine Intern
    Professional Medical Medicine - Government Medical College M.B.B.S.

    Selected Publications

    Journal Article

    1. Bindal P, Najjar M, Koehn K, Godara A, Sborov DW, McClune B, Julian K, Wagner C, Mohyuddin GR (2023). Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials. Leuk Lymphoma, 1-4.
    2. Siddiqui NS, Klein A, Godara A, Buchsbaum RJ, Hughes MC (2022). Predicting In-Hospital Mortality After Acute Myeloid Leukemia Therapy: Through Supervised Machine Learning Algorithms. JCO Clin Cancer Inform, 6, e2200044.
    3. McInturf G, Younger K, Sanchez C, Walde C, Abdallah AO, Ahmed N, Shune L, Sborov DW, Godara A, McClune B, Sinclair CT, Mohyuddin GR (2022). Palliative care utilization, transfusion burden, and end-of-life care for patients with multiple myeloma. Eur J Haematol, 109(5), 559-565.
    4. Vardell VA, Ermann DA, Tantravahi SK, Haaland B, McClune B, Godara A, Mohyuddin GR, Sborov DW (2022). Impact of academic medical center access on outcomes in multiple myeloma. Am J Hematol, 98(1), 41-48.
    5. Mohyuddin GR, Ahlstrom JM, Chmielewski CA, Sweeney NW, Molina TH, Cheung CS, Ballard EW, Seng FF, Van Oekelen O, Godara A, McClune B, Sborov D (2022). A survey on the patient perspective on cure in multiple myeloma. Lancet Haematol, 9(10), e716-e719.
    6. Godara A, Wang AY, Arkun K, Fogaren T, Qamar AS, McPhail ED, Kryzanski J, Riesenburger R, Comenzo R (2022). Unraveling a rare cause of spinal stenosis: Coexistent AL and ATTR amyloidosis involving the ligamentum flavum. Surg Neurol Int, 13, 12.
    7. Alderuccio JP, Olszewski AJ, Evens AM, Collins GP, Danilov AV, Bower M, Jagadeesh D, Zhu C, Sperling A, Kim SH, Vaca R, Wei C, Sundaram S, Reddy N, Dalla Pria A, DAngelo C, Farooq U, Bond DA, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Kassam S, Yazdy M, Rabinovich E, Post FA, Varma G, Karmali R, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach C, Straker-Edwards A, Klein A, Blum KA, Boughan KM, Mian A, Haverkos BM, Orellana-Noia VM, Kenkre VP, Zayac A, Maliske SM, Epperla N, Caimi P, Smith SE, Kamdar M, Venugopal P, Feldman TA, Rector D, Smith SD, Stadnik A, Portell CA, Lin Y, Naik S, Montoto S, Lossos IS, Cwynarski K (2021). HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. Blood Adv, 5(14), 2852-2862.
    8. Godara A, Riesenburger RI, Zhang DX, Varga C, Fogaren T, Siddiqui NS, Yu A, Wang A, Mastroianni M, Dowd R, Nail TJ, McPhail ED, Kurtin PJ, Theis JD, Toskic D, Arkun K, Pilichowska M, Kryzanski J, Patel AR, Comenzo R (2021). Association between spinal stenosis and wild-type ATTR amyloidosis. Amyloid, 28, 1-8.
    9. Zayac AS, Evens AM, Danilov A, Smith SD, Jagadeesh D, Leslie LA, Wei C, Kim SH, Naik S, Sundaram S, Reddy N, Farooq U, Kenkre VP, Epperla N, Blum KA, Khan N, Singh D, Alderuccio JP, Godara A, Yazdy MS, Diefenbach C, Rabinovich E, Varma G, Karmali R, Shao Y, Trabolsi A, Burkart M, Martin P, Stettner S, Chauhan A, Choi YK, Straker-Edwards A, Klein A, Churnetski MC, Boughan KM, Berg S, Haverkos BM, Orellana-Noia VM, DAngelo C, Bond DA, Maliske SM, Vaca R, Magarelli G, Sperling A, Gordon MJ, David KA, Savani M, Caimi P, Kamdar M, Lunning MA, Palmisiano N, Venugopal P, Portell CA, Bachanova V, Phillips T, Lossos IS, Olszewski AJ (2021). Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. Haematologica, 106(7), 1932-1942.
    10. George KM, Hernandez NS, Breton J, Cooper B, Dowd RS, Nail J, Yu A, Mastroianni M, Wang A, Godara A, Zhang D, Arkun K, Patel AR, Varga C, Soto O, Kryzanski J, Comenzo R, Riesenburger R (2021). Lumbar ligamentum flavum burden: Evaluating the role of ATTRwt amyloid deposition in ligamentum flavum thickness at all lumbar levels. Clin Neurol Neurosurg, 206, 106708.
    11. Hachem H, Godara A, Schroeder C, Fein D, Mann H, Lawlor C, Marshall J, Klein A, Poutsiaka D, Breeze JL, Joshi R, Mathew P (2021). Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNFα-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure. J Clin Transl Sci, 5(1), e146.
    12. Godara A, Siddiqui NS, Munigala S, Dhawan R, Kansagra AJ, Rapoport AP, Yared JA, Dahiya S (2020). Length of Stay and Hospital Costs for Patients Undergoing Allogeneic Stem-Cell Transplantation. JCO Oncol Pract, 17(3), e355-e368.
    13. George KM, Hernandez NS, Breton J, Cooper B, Dowd RS, Nail J, Yu A, Mastroianni M, Wang A, Godara A, Zhang D, Arkun K, Patel AR, Varga C, Soto O, Kryzanski J, Comenzo R, Riesenburger R (2020). Increased thickness of lumbar spine ligamentum flavum in wild-type transthyretin amyloidosis. J Clin Neurosci, 84, 33-37.
    14. Godara A, Palladini G (2020). Monoclonal Antibody Therapies in Systemic Light-Chain Amyloidosis. Hematol Oncol Clin North Am, 34(6), 1145-1159.
    15. Saif MW, Hachem H, Purvey S, Hamal R, Zhang L, Siddiqui NS, Godara A, Diasio RB (2020). Pharmacogenetic Variants in the DPYD and TYMS Genes are Clinically Significant Predictors of Fluoropyrimidine Toxicity: Are We Ready for Use in our Clinical Practice. Arch Pharmacol Ther, 2(1), 6-8.

    Case Report

    1. Godara A, Wang AY, Arkun K, Fogaren T, Qamar AS, McPhail ED, Kryzanski J, Riesenburger R, Comenzo R (2022). Unraveling a rare cause of spinal stenosis: Coexistent AL and ATTR amyloidosis involving the ligamentum flavum. Surg Neurol Int, 13, 12.
    2. Godara A, Migliozzi DR, Pilichowska M, Goyal N, Varga C, Gordon CE (2020). Use of Eculizumab in Transplant-Associated Thrombotic Microangiopathy in a Patient With Polycystic Kidney Disease Immediately Post-Kidney Transplant: A Case Report. Kidney Med, 2(5), 652-656.

    Letter

    1. Zhang Y, Godara A, Pan S, Toskic D, Mann H, Sborov D, Comenzo R, Kansagra A (2022). Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma. [Letter to the editor]. Ann Hematol, 101(9), 2119-2121.
    2. Godara A, Toskic D, Albanese J, Rosenthal B, Siddiqui NS, Kugelmass A, Zhou P, Fogaren T, Varga C, Landau HJ, Comenzo RL (2020). Involved free light chains <10 mg/L with treatment predict better outcomes in systemic light-chain amyloidosis. [Letter to the editor]. Am J Hematol, 96(1), E20-E23.

    Other

    1. Hachem H, Godara A, Schroeder C, Fein D, Mann H, Lawlor C, Marshall J, Klein A, Poutsiaka D, Breeze JL, Joshi R, Mathew P (2021). Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNF-α antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure. medRxiv. United States.

  • Podcasts & News

    Huntsman Cancer Institute News

    The Scope Podcast